Antibody Drug Conjugate Development and Manufacture

With the recent approvals of brentuximab vedotin (Adcetris) and ado-trastuzumab emtansine (Kadcyla,T-DM1), antibody–drug conjugates (ADCs)are a rapidly growing area in oncology with great potential. Development and manufacture of ADCs can be a challenge with the requirement to handle both biologics and highly potent small molecule toxins. This webinar will look at some of the issues with developing and manufacturing ADCs